immuno-oncology

News
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
01/29/2020
            – Application is being reviewed under FDA's Real-Time Oncology Review pilot program – SOUTH SAN FRANCISCO, Calif. – January 26, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:...
            – Application is being reviewed under FDA's Real-Time Oncology Review pilot program – SOUTH SAN FRANCISCO, Calif. – January 26, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:...
       ...
01/29/2020
IO Learning
News
FDA Approves Combination Immunotherapy for Renal Cell Carcinoma
04/17/2018
The FDA has approved the combination of nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) to treat intermediate- or poor-risk advanced renal cell carcinoma that was previously untreated. The approval is based on data...
The FDA has approved the combination of nivolumab and ipilimumab (Opdivo and Yervoy, Bristol-Myers Squibb Co.) to treat intermediate- or poor-risk advanced renal cell carcinoma that was previously untreated. The approval is based on data...
The FDA has approved the...
04/17/2018
IO Learning
News
HalioDx performed development work for ipsogen® JAK2 510(k) clearance by QIAGEN
03/30/2017
Marseille, France, March 30, 2017 - HalioDx SAS, an immuno-oncology diagnostic company, today announced that its R&D collaboration with QIAGEN N.V., a leading global provider of Sample to Insight solutions, has resulted in a U.S. Food and...
Marseille, France, March 30, 2017 - HalioDx SAS, an immuno-oncology diagnostic company, today announced that its R&D collaboration with QIAGEN N.V., a leading global provider of Sample to Insight solutions, has resulted in a U.S. Food and...
Marseille, France, March 30,...
03/30/2017
IO Learning
Interview
Immunotherapies and the Future of Cancer Care
03/08/2016
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five...
03/08/2016
Journal of Clinical Pathways
Research in Review
Suicide Gene Therapy Safe and Effective in Treating Prostate Cancer
12/15/2015
JCP Editors
A long-term clinical trial of suicide gene therapy has shown that it safely and effectively destroys prostate cancer cells. The method alters the genetic composition of cancer cells so that they trigger the immune...
A long-term clinical trial of suicide gene therapy has shown that it safely and effectively destroys prostate cancer cells. The method alters the genetic composition of cancer cells so that they trigger the immune...
A...
12/15/2015
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use